Sleep and Physical Activity in Patient and Caregiver Dyads Following Allogeneic Hematopoietic Cell Transplantation
M.D. Anderson Cancer Center
Summary
To understand the changes in health-related quality of life of patients and caregivers after allogeneic hematopoietic cell transplantation.
Description
Primary Objectives * Assess the feasibility and acceptability of obtaining objective sleep and physical activity measures in participants receiving allogeneic HCT and their caregivers during hospitalization (T2), and after discharge (T3) using Fitbits. * Feasibility will be determined by the percentage of participants and caregivers who wear the Fitbit Inspire 3 for sleep and physical activity data at T2, and T3. For the purposes of this study, if ≥70% of participants and caregivers will wear the Fitbit for 5 of 7 nights for sleep data and at least 10 hours during waking hours for 5 of 7 days…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Eligibility Criteria * Participants and caregivers ages 18 years and older. * Participants diagnosed with a hematologic malignancy with a scheduled allogeneic HCT. * Caregivers identified by participant as the primary caregiver. * Participants and caregivers able to read, speak, and consent in English. * Participants and caregivers able to understand and be willing to sign a written informed consent document. * Participants and caregivers must have internet access via smart phone or tablet with the capacity to 1) download the Fitbit app and 2) complete study assessments with study Exclusion…
Interventions
- DeviceFitbit
You will wear the tracker on your wrist like a watch and it will continuously (non-stop) monitor your activity, sleep, and heart rate. Functional testing will be completed with a research team member and will consist of 2 tests: testing your grip strength by having you squeeze a measuring device 3 times with your dominant hand and measuring how many minutes it takes for you to walk 15 feet.
- OtherQuestionnaire
Complete questionnaires at 3 timepoints, at the time of enrollment on the day of allogeneic hematopoietic cell transplantation, 8 days after allogeneic hematopoietic cell transplantation, and 7 days after hospital discharge.
Location
- MD Anderson Cancer CenterHouston, Texas